SEC Form SC 13G filed by Agilent Technologies Inc.
$A
Biotechnology: Laboratory Analytical Instruments
Industrials
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $135.00 → $145.00 | Underweight → Equal Weight | Barclays |
| 8/28/2024 | $157.00 | Overweight | Wells Fargo |
| 7/10/2024 | $135.00 → $150.00 | Neutral → Buy | Citigroup |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/3/2024 | $135.00 | Hold | Jefferies |
| 4/5/2024 | $145.00 → $163.00 | Hold → Buy | Stifel |
| 12/13/2023 | $140.00 | Outperform | Wolfe Research |
| 12/12/2023 | $130.00 → $133.00 | Buy → Neutral | BofA Securities |
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously
Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00
Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E
Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans
Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag
LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of
Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E
Agilent Technologies Inc. (NYSE:A) today announced August Specht, Ph.D., has been named the company's Chief Technology Officer. Specht, previously vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific, will join Agilent on June 9. "We are thrilled to welcome August Specht to the Agilent team as we further accelerate the pace of innovation in an ever-changing world through our Ignite Transformation," said Padraig McDonnell, Agilent president and CEO. "August brings more than 25 years of experience designing, developing, and marketing analytical instruments, software, and consumables that support scientific advancement around the worl
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p
Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m